Nanopore Sensor Advances Early Detection of Parkinson's and ALS
BRIC-RGCB unveils nanopore technology for detecting low-concentration biomarkers in neurodegenerative diseases.
Researchers at the Biotechnology Research and Innovation Council-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) have made a significant breakthrough in the detection of neurodegenerative diseases. They have developed an innovative nanopore-based sensing technology capable of identifying biomarkers associated with Parkinson's disease and amyotrophic lateral sclerosis (ALS) at early stages.
Breakthrough in Biomarker Detection
Traditional methods often struggle to detect biomarkers present in low concentrations. However, the new technology from BRIC-RGCB, led by Mahendran K R, utilizes short peptides that self-assemble into nanopores of varying sizes. This allows for the differentiation between disease-associated and non-disease-associated biomarkers, even in complex protein mixtures.
The study, published in the journal Nature Nanotechnology, highlights how these sensors could revolutionize early detection and monitoring of neurodegenerative diseases. The platform's ability to detect disease biomarkers directly from biological fluids like blood signifies a potential leap forward in point-of-care diagnostics.
Potential for Broader Applications
The researchers suggest that this nanopore technology could be adapted to detect biomarkers associated with other diseases, including cancer. The design draws inspiration from natural structures and combines these with computationally designed pores, potentially leading to more sensitive future technologies.
This promising research was a collaborative effort involving scientists from Constructor University in Germany and the CSIR-Indian Institute of Chemical Biology in Kolkata. The project received support from the Department of Biotechnology, the Department of Science and Technology, the Indian Council of Medical Research, and the Council of Scientific and Industrial Research.
By addressing the challenges of detecting low-concentration biomarkers, the BRIC-RGCB team's work could pave the way for earlier diagnosis and treatment of debilitating neurodegenerative diseases, providing hope for improved patient outcomes.